BioCryst secures FDA approval for Orladeyo oral pellets, expanding preventive HAE therapy to children ages 2 to under 12.
Patna: The National Institute of Pharmaceutical Education and Research (NIPER), Hajipur, on Friday inked a memorandum of ...
Based on research and analysis of the global microecology market, as well as the evaluation of relevant companies in the ...
The U.S. Food and Drug Administration has approved an oral pellet formulation of BioCryst Pharmaceuticals' drug to prevent hereditary angioedema attacks in children aged 2 to under 12, the company ...
Generic drugmaker Granules India’s Hyderabad-based pharmaceutical formulation intermediates and finished dosages manufacturing subsidiary Granules Life Sciences (GLS) has received establishment ...
The U.S. Food and Drug Administration has approved an oral pellet formulation of BioCryst Pharmaceuticals' drug to prevent ...
To treat their pain, anxiety and sleep problems, millions of Americans turn to cannabis, which is now legal in 40 states for ...
TipRanks on MSN
BioCryst gains FDA approval for pediatric HAE drug
BioCryst ( ($BCRX) ) has provided an announcement. On December 12, 2025, BioCryst Pharmaceuticals announced the FDA approval of its new drug ...
ORLADEYO is now the first and only targeted oral prophylactic therapy for patients with HAE aged 2 and above. A capsule ...
Stocktwits on MSN
Why are retail traders going gaga over BioCryst Pharma stock today?
BioCryst said the approval follows positive interim data from a trial that showed the drug is safe and well-tolerated. ・The ...
Novo Nordisk on Friday launched its blockbuster weight-loss drug Ozempic in India, beginning at Rs 8,800 a month or four ...
The FDA has approved berotralstat oral pellets for prophylactic use in patients aged 2 to than 12 years with hereditary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback